CVLLY (CellaVision AB) Cyclically Adjusted Revenue per Share: $1.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVLLY CellaVision AB CVLLY
95 GF Score
Price $7.06
GF Value $8.88
! 2 Warning Signs
View Full Analysis

What is CellaVision AB Cyclically Adjusted Revenue per Share?

CellaVision AB CVLLY +12.06% 95 Cyclically Adjusted Revenue per Share is $1.35 as of Jun. 2026. GuruFocus rates CVLLY with a GF Score™ of 95/100 and a GF Value™ of $8.88. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CellaVision AB's adjusted revenue per share for the three months ended in Jun. 2026 was $0.440. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.35 for the trailing ten years ended in Jun. 2026.

During the past 12 months, CellaVision AB's average Cyclically Adjusted Revenue Growth Rate was 7.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of CellaVision AB was 19.10% per year. The lowest was 10.80% per year. And the median was 16.10% per year.

As of today (2026-08-08), CellaVision AB's current stock price is $7.06. CellaVision AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $1.35. CellaVision AB's Cyclically Adjusted PS Ratio of today is 5.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CellaVision AB was 37.78. The lowest was 4.67. And the median was 19.60.


CellaVision AB  (OTCPK:CVLLY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CellaVision AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.06/1.35
=5.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CellaVision AB was 37.78. The lowest was 4.67. And the median was 19.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CellaVision AB Cyclically Adjusted Revenue per Share Related Terms


CellaVision AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Cyclically Adjusted Revenue per Share Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CellaVision AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.49 1.35

CVLLY vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, CellaVision AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Cyclically Adjusted PS Ratio falls into.


CVLLY
95GF Score
CellaVision AB CVLLY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CellaVision AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.44/134.6100*134.6100
=0.440

Current CPI (Jun. 2026) = 134.6100.

CellaVision AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.168 101.138 0.224
201612 0.166 102.022 0.219
201703 0.219 102.022 0.289
201706 0.190 102.752 0.249
201709 0.161 103.279 0.210
201712 0.190 103.793 0.246
201803 0.197 103.962 0.255
201806 0.219 104.875 0.281
201809 0.198 105.679 0.252
201812 0.258 105.912 0.328
201903 0.234 105.886 0.297
201906 0.251 106.742 0.317
201909 0.206 107.214 0.259
201912 0.333 107.766 0.416
202003 0.286 106.563 0.361
202006 0.266 107.498 0.333
202009 0.208 107.635 0.260
202012 0.328 108.296 0.408
202103 0.329 108.360 0.409
202106 0.338 108.928 0.418
202109 0.320 110.338 0.390
202112 0.379 112.486 0.454
202203 0.356 114.825 0.417
202206 0.383 118.384 0.435
202209 0.271 122.296 0.298
202212 0.308 126.365 0.328
202303 0.278 127.042 0.295
202306 0.330 129.407 0.343
202309 0.318 130.224 0.329
202312 0.410 131.912 0.418
202403 0.342 132.205 0.348
202406 0.375 132.716 0.380
202409 0.366 132.304 0.372
202412 0.356 132.987 0.360
202503 0.403 132.825 0.408
202506 0.420 133.699 0.423
202509 0.393 133.480 0.396
202512 0.445 133.390 0.449
202603 0.374 133.560 0.377
202606 0.440 134.610 0.440

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $1.35 mean?
CellaVision AB (CVLLY) has a Cyclically Adjusted Revenue per Share of $1.35 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Cyclically Adjusted Revenue per Share too high?
CellaVision AB's current Cyclically Adjusted Revenue per Share is $1.35. Overall, CellaVision AB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
CellaVision AB's Cyclically Adjusted Revenue per Share of $1.35 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CellaVision AB and its competitors. CellaVision AB's current Cyclically Adjusted Revenue per Share is $1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CVLLY) has a current Cyclically Adjusted Revenue per Share of $1.35. The stock's GF Value™ is $8.88, compared to a current price of $7.06 — trading 20.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $1.35. CellaVision AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Cyclically Adjusted Revenue per Share is $1.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 20.5% below its estimated GF Value™ of $8.88.

Key valuation signals for CVLLY:

  • Cyclically Adjusted Revenue per Share: $1.35
  • GF Value™: $8.88 vs. price of $7.06 (20.5% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
95GF Score

Get the complete analysis for CVLLY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price
$8.88
GF Value